Abu Dhabi’s Mubadala invests in Swiss biotech firm Rejuveron
Founded by Aksana Labokha in 2019, Rejuveron is focused on developing therapies to prevent or reverse ageing-related diseases and extend lifespans.
, the sovereign wealth fund of Abu Dhabi, has invested in the Swiss biotech company Rejuveron Life Sciences AG to finance the development of drugs addressing ageing effects.
The company raised $75 million in a Series B funding round at a valuation reportedly of nearly $400 million.
The investment round was co-led led by Catalio Capital Management, a life-sciences investment firm, and Apeiron Investment Group, the private investment company of German businessman Christian Angermayer, as per a statement shared on Zawya.
"The UAE, the Kingdom of Saudi Arabia and other Gulf countries have clearly outlined strategic goals to promote a healthcare system that embraces longevity and preventive medicine," Aksana Labokha, CEO of Rejuveron, told Bloomberg Middle East.
Founded in 2019 by Labokha, Rejuveron is focused on developing therapies to prevent or reverse ageing-related diseases and extend lifespans. It conducts clinical trials for treatments targeting retinitis pigmentosa and sarcopenia—rare eye diseases causing progressive vision loss.
The company plans to acquire a stake in Boost Neuroscience, a Catalio-backed company developing brain synapse regeneration technologies. Additionally, Rejuveron plans to establish an office in Abu Dhabi to support its expansion in the Middle East.
Rejuveron said joining the MENA region's thriving ecosystem will help it achieve development goals and invigorate healthcare delivery, which is crucial for advancing preventive medicine.
Founded in 2017, Mubadala manages a $284 billion portfolio worldwide on six continents. It is headquartered in Abu Dhabi and has offices in London, Moscow, New York, and Beijing.
For any press related queries or to share your press releases, write to us at
[email protected].
Edited by Kanishk Singh
